Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Council Bluffs, IA
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Council Bluffs, IA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Augusta, KA
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Augusta, KA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Wichita, KA
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Wichita, KA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Edina, MN
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Edina, MN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Kansas City, MO
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Bellevue, NE
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Bellevue, NE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Norfolk, NE
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Norfolk, NE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Omaha, NE
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Rochester, NY
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Charlotte, NC
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Hickory, NC
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Hickory, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Raleigh, NC
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Akron, OH
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Akron, OH
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Dakota Dunes, SD
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Dakota Dunes, SD
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Knoxville, TN
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Nashville, TN
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Murray, UT
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Research Site
mi
from
Brampton,
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Research Site
mi
from
Brampton,
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Research Site
mi
from
Cincinnati, MO
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Research Site
mi
from
Cincinnati, MO
Click here to add this to my saved trials
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated:  12/22/2017
Clinical Research Facility
mi
from
Rocky Mount, NC
A Study to Evaluate the Efficacy of MEDI7510 in Older Adults
A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults
Status: Enrolling
Updated: 12/22/2017
Clinical Research Facility
mi
from
Rocky Mount, NC
Click here to add this to my saved trials
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated:  12/23/2017
Jefferson County
mi
from
Louisville, KY
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated: 12/23/2017
Jefferson County
mi
from
Louisville, KY
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
UAB Lung Health Center
mi
from
Birmingham, AL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
UAB Lung Health Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Vapahcs 111P
mi
from
Palo Alto, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Vapahcs 111P
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
GLAHS Sepulveda
mi
from
Sepulveda, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
GLAHS Sepulveda
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Rehabilitation Clinical Trial Center
mi
from
Torrance, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Rehabilitation Clinical Trial Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Hospital for Special Care
mi
from
New Britain, CT
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Bay Pines Va Medical Center
mi
from
Bay Pines, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Bay Pines Va Medical Center
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
mi
from
Pembroke Pines, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
LSUHSC Shreveport
mi
from
Shreveport, LA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
LSUHSC Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
VAMC-Reno
mi
from
Reno, NV
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
VAMC-Reno
mi
from
Reno, NV
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
North Shore Universtiy Hospital
mi
from
New Hyde Park, NY
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
North Shore Universtiy Hospital
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
SVMMC
mi
from
Toledo, OH
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
SVMMC
mi
from
Toledo, OH
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Hershey Medical Center
mi
from
Hershey, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Frank Sciurba
mi
from
Pittsburgh, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Frank Sciurba
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
MUSC
mi
from
Charleston, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Harker Heights, TX
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Harker Heights, TX
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Medvamc
mi
from
Houston, TX
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Medvamc
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
McGuire VA
mi
from
Fredericksburg, VA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
McGuire VA
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
CHU du Sart Tilman (B35)
mi
from
Angleur,
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
CHU du Sart Tilman (B35)
mi
from
Angleur,
Click here to add this to my saved trials